Top Stories
The treatment was previously approved for pharmacologically-induced mydriasis in 2023.
Some cell and gene therapy processing platforms will be banned from exportation, while target-discovery related technologies may be exported if given a regulatory green light.
The EMA's Committee for Medicinal Products for Human Use also recommended approval of Revolution Medicines' pancreatic cancer drug.
The funding will help the biotech move its two lead programmes into the clinic for autosomal dominant polycystic kidney disease in 2027 and 2028, respectively.
The biotech's shares climbed roughly 25% during its first day of trading on Friday.
Conference News
Confirmed as delivering a positive readout in the summer, Moderna and Merck & Co.'s INTerpath-001 trial has been described as a potential landmark study for individualised neoantigen vaccines. With detailed results due to be presented at next week's European Society for Medical Oncology (ESMO) C
20 scientific presentations underscore the breadth of AbbVie's leadership in Inflammatory Bowel Disease (IBD) research programsLatest long-term and real-world data with SKYRIZI®(risankizumab) and RINV...
SHANGHAI, Oct. 17, 2026 /PRNewswire/ -- Vivacta Biotechnology (Shanghai) Co., Ltd. ("Vivacta Bio"), a company spun out of the in vivo CAR-T platform of Beijing Grit Biotherapeutics Co., Ltd. ("Grit Bi...
– PCF Think Tank aims to increase adoption of radiopharmaceuticals as major oncology therapeutic platform in prostate cancer treatment and to other tumor types –– New members Orano Med, Telix and Siem...
WALTHAM, Mass., Oct. 18, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company committed to developing next-generation therapies that elevate the sta...
